NCT07133178View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

February 6, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

November 30, 2027

Conditions
Chikungunya Virus Infection
Interventions
BIOLOGICAL

VLA1553

Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine

BIOLOGICAL

Control

Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization

All Listed Sponsors
lead

Valneva Austria GmbH

INDUSTRY